Background: Validated assays are essential to generate data with defined specificity, consistency, and reliability. Although the process of validation is required for applying immunoassays in the context of clinical studies, reports on systematic validation of in vitro T cell assays are scarce so far. We recently validated our HLA-peptide multimer staining assay in a systematic manner so as to qualify the method for monitoring antigen-specific T cell responses after immunotherapy.
INTRODUCTION
Active immunotherapy essentially relies on the stimulation of antigen-specific T cells. In cancer immunotherapy, either by checkpoint blockade or in experimental approaches like adoptive T cell transfer or vaccination, it is therefore crucial to understand how anti-tumor T cells can be activated and maintained in treated patients. Hence, in vitro assessment of (antigen-specific) T cell responses is nowadays an essential element in clinical development. This makes reliable immunomonitoring assays essential to substantiate the outcome of clinical studies (1) . The use of validated assays to monitor clinical trials has been made a legal pre-requisite in USA and in Europe, in line with Good Clinical Laboratory Practice (GCLP) (2) (3) (4) (5) (6) . Although validation does not primarily improve performance, it indicates the strengths, weaknesses, operational range and repeatability of assays while adding credibility and reliability to the data generated.
Directives that detail the general steps to be taken during the validation of a bioassay do exist, but their translation to monitor immune cells is scarce so far (2, (7) (8) (9) . One reason for the lack of solid guidelines is most probably the inherent complexity of immunoassays that measure the attributes or the function(s) of cell subsets, especially when these are present at low frequency in a complex mixture. Commonly employed immunomonitoring assays which focus on quantifying the frequency and/or function of immune effector cells include HLA-multimer staining (multimer assay), Elispot (Enzyme-linked immune-spot assay), and intracellular cytokine staining (10) . The evolution of these assays in single laboratories across the world has led to several laboratory-specific characteristics, potentially including anomalies or artifacts within the assays. These inter-laboratory variations have been addressed in the recent years by several harmonization panels for HLA-multimer staining, ELISPOT, and intracellular cytokine staining that were organized by the Cancer Immunotherapy Consortium (CIC) of the Cancer Research Institute, USA (CRI) and the CIMT Immunoguiding Program (CIP) of the Association for Cancer Immunotherapy, Europe (CIMT). The importance and impact of such efforts to minimize inter-laboratory variabilities are well known (11) (12) (13) (14) (15) (16) . They also enable comparability and objective evaluation of immunomonitoring data from multi-centric clinical trials. In addition, participating laboratories are then able to improve the performance of their assays based on harmonization guidelines.
Since it was first described in 1996, the multimer assay has established itself as an indispensable tool for the detection of rare antigen specific CD8 1 T cells (17) (18) (19) . In principle, fluorescent, peptide-loaded HLAmultimers bind to cognate T cell receptors (TCR) on antigen-specific T cells and are subsequently detected by flow cytometry, independent of the T cell functionality. Based on a series of recent technological developments, the method is nowadays established in many labs and can be used for fast and high-throughput screening of Tcell antigen specificities (20) (21) (22) . In parallel, a number of reports have proposed guidelines for optimization and standardization of both the reagents and the assay conditions (18, 19, 23) .
Several validation studies have previously focused on the repeatability and linearity of the multimer assay (24) (25) (26) . These studies indicated low background levels, good reproducibility as well as a high degree of linearity of the assay. However, a comprehensive validation of the entire method is still lacking. Here, we validate, in addition to the above mentioned parameters, the sensitivity and robustness of the multimer assay. We describe each of these parameters, the strategy employed for testing them and the results of the validation process. In addition, we provide a step-by-step procedure for multimer validation that may also be applied for further T cell immunoassays.
MATERIALS AND METHODS
This section is organized in compliance with the framework for minimal information about T-cell assays (www.miataproject.org) (27) .
Samples

Media and buffers
The media used were: T-cell medium (TCM): IMDM (Lonza, Verviers, Belgium), 10% heat-inactivated (h.i.) human AB serum (Life Technologies, Darmstadt, Germany), 1% penicillin/streptomycin (Sigma-Aldrich, Steinheim, Germany) and 50 mM beta-mercaptoethanol (Merck, Darmstadt, Germany); thawing medium: IMDM, 2.5% h.i. human AB serum, 1% penicillin/streptomycin, 50 mM beta-mercaptoethanol and 3 mg/ml DNase I (Sigma-Aldrich, Munich, Germany); freezing solution: h.i. fetal calf serum (FCS, Biochrom AG, Berlin, Germany) containing 10% DMSO (Merck KGaA, Darmstadt, Germany). For cell staining, the buffers were: multimer buffer: PBS (inhouse preparation) containing 0.02% sodium azide, 2 mM EDTA (Roth, Karlsruhe, Germany) and 2% h.i. FCS; multimer solution: PBS containing 0.02% sodium azide, 2 mM EDTA and 50% h.i. FCS; fix solution: multimer buffer containing 1% formaldehyde (36% w/v; Sigma-Aldrich).
PBMC samples
We used PBMCs from 5 HLA-A*02 (1) CMV seropositive donors (B1050, B1053, B1054, B1071, and B1093), 3 HLA-A*02 (1) CMV seronegative donors (B1051, B1055, and B1057) and 5 HLA-A*02 (-) donors (B1052, B1058, B1060, B1061, and B1062), all obtained through venipuncture as buffy coats from the Center for Clinical Transfusion Medicine GmbH of the University Hospital in Tuebingen, after informed consent. PBMCs were isolated by layering the diluted buffy coats (1:4 in sterile PBS) over Biocoll separating solution (Biochrom AG). Cells were subsequently washed twice with PBS and counted using 0.1% trypan blue solution (Merck). Viability of cells was over 80%. 10-20 x 10 6 cells were frozen/ml of freezing solution at 2808C in Mr. Frosty TM containers (Nalgene, Thermo Scientific, Germany). Within a week, the frozen vials were transferred to the gaseous phase of liquid nitrogen. On the day of the experiment, cells were thawed in a 378C water bath and diluted to 5 to 10 times the freezing volume in thawing medium. Following one wash with serum free medium, the cells were counted with trypan blue and further used only if the viability was > 80%. Prior to the validation experiments, PBMCs from all the HLA-A*02 (1) donors were prescreened for the presence of CMV-pp65 and Flu-M1 specific CD8 (1) cells by multimer staining. Based on this pre-screening, the antigen specificities were initially classified into high (> 1%), intermediate (0.1 to 1%) and low frequencies (< 0.1%) of multimer (1) CD8 (1) cells, This classification was later confirmed by VALIDATION OF THE HLA-MULTIMER STAINING ASSAY the precision experiments and is shown in Supporting Information Figure 1 .
Assays
Peptides, HLA-peptide monomers, and multimers
Peptides were synthesized in-house using an automated peptide synthesizer 433A (Applied Biosystems, Foster City, USA) as described previously (28) . For HLA-monomer refolding, peptides were diluted at 10 mg/ml in 100% DMSO immediately before use; for functional assays (Fig.  2 ), they were dissolved at 1 mg/ml in 10% DMSO, aliquoted and stored at 2808C until use. Biotinylated HLA (HLA-A*02:01)-peptide monomers were refolded in-house using the GILGFVFTL peptide from the Influenza virus matrix protein M1 (Flu), NLVPMVATV from the Human Cytomegalovirus pp65 protein (CMV) and YLLPAIVHI peptide from the ubiquitously expressed DDX5 human protein. Monomers (2 mg/ml) were aliquoted and stored at 2808C. HLA-peptide multimers (multimers) were then generated by incubating the monomers with streptavidin-PE or streptavidin-APC (Life Technologies) at a 4:1 molar ratio (17) . After addition of 1 mM biotin (B4501, Sigma-Aldrich), the multimers were aliquoted and frozen at 2808C in freezing solution containing 1.67% human serum albumin (AlbiominV R , Biotest, Dreieich, Germany), 0.067% sodium azide, 3.34X protease inhibitor (cOmplete TM , Sigma-Aldrich), 42% v/v glycerol (Roth) and 7 mM TBS, such that the final mixture contained 14% (v/v) glycerol (23) . The stock concentrations of PE-and APC-conjugated multimers were 310 mg/ml and 485 mg/ml respectively.
Multimer staining
The multimer staining protocol was essentially that proposed by the CIP (http://www.cimt.eu/workgroups/ cip). Briefly, 2 x 10 6 cells (unless mentioned otherwise) in 100 ml PBS were added per well of a 96 well U bottom plate and mixed with 100 ml multimer buffer. Cells were centrifuged at 472 g for 5 min at 48C and the supernatant was removed. Relevant multimers were diluted to 5 mg/ml in multimer solution, centrifuged at 16,000g for 10 min at 48C, and the supernatant was transferred to a fresh tube. Cells were then incubated with 50 ml of this supernatant at room temperature in the dark. After 30 min, cells were washed once with 150 ml multimer buffer and resuspended in 50 ml multimer buffer containing CD4-FITC (clone HP2/6, in-house production) diluted 1:100, CD8 PE-Cy7 (clone SFCI21-Thy2D3, Beckman Coulter) diluted 1:400 and Aqua Live/Dead (Life technologies) diluted 1:50-1:100. After a 20 min final incubation at 48C, cells were washed with multimer buffer, resuspended in 200 ml fix solution and stored at 48C until analysis by flow cytometry.
Data Acquisition
Flow cytometry
Within 24 h after staining/fixation, cells were acquired on an LSR-Fortessa SORP cytometer (BD Biosciences, Heidelberg, Germany) operated through the BD FACSDiva TM software (Version 6.1.2). Prior to each measurement, a performance test of the PMTs was performed using the cytometer setup and tracking (CS&T) beads (BD Biosciences). Spectral overlap was compensated using AbC and ArC beads (both from Life Technologies). Unless mentioned, 1x10 6 cells were acquired per test. The resulting data were saved as FCS 3.0 files and were subsequently analyzed using FlowJo Mac version 9.7.5 or Windows version V10 (FlowJo LLC, Ashland, OR).
Data Analysis and Validation Steps
Gating strategy and data management PBMCs were serially gated following the hierarchy: Time parameter histogram: cells that were nonlinearly acquired over time were gated out . FSC-A vs FSC-H dot plot: gate on singlets. FSC-A vs Aqua Live/Dead dot plot: gate on living cells. FSC-A vs SSC-A dot plot: gate on lymphocytes. CD8 PE-Cy7 vs CD4 FITC dot plot: gate on CD4 (low) cells. CD8 PE-Cy7 vs multimer (PE/APC): gates on CD8 (1) and CD8 (1) multimer (1) cells (See example of a full analysis in Supporting Information Fig. 2 ). Cells within the CD8 1 gate were further plotted in a multimer-PE vs multimer-APC dot plot to assess double multimer positive cells (only for specificity experiments). All the raw data generated from the validation experiments have been archived on our in-house server and are available upon request.
Validation procedure
Specificity, precision, linearity, sensitivity, and robustness of the multimer staining assay were validated for two -PE and -APC labeled HLA-A*0201 multimer specificities. Each of the addressed parameters was defined as follows. Specificity: ability of a given multimer to detect cells bearing a TCR specific for a particular peptide-HLA complex and to distinguish these antigen-specific cells within a cell mixture. Precision: closeness of results obtained from individual measurements. Linearity: linear correlation between the measured percentage and the actual/predicted percentage of multimer (1) cells within the sample. Sensitivity: ability to record small variations in the percentage of antigen specific cells in the assay. Robustness: ability of the assay to withstand changes in technical/assay variables. A validation plan, detailing the various approaches and experiments to assess each parameter, the acceptance criteria, the protocols and equipment as well as the methods for collection, analysis and archiving of the data, was first prepared and reviewed by three experienced cytometry users. All experiments were performed according to this plan. The data were analyzed by one operator (except for the inter-individual variability experiments that were performed by three operators from the same research group). A detailed validation report containing the experiment s summary, results, statistical analysis and interpretations was then prepared by the main operator and was reviewed by two cytometry users. Parameters and recommendations for validation are summarized in Figure 1 . A flow chart showing the approach to be taken from the step of assay development to the validation process and troubleshooting is shown in Supporting Information Figure 3 ; Supporting Information Table 1 presents all results in details including acceptance criteria, exploratory aspects and key findings.
Statistics
All data including acceptance criteria fulfillment were statistically evaluated. In the specificity experiments, mean of percentage of multimer (1) CD8 (1) cells was calculated for each multimer among all donors tested and in case of a clear outlier result, the median was also reported. Precision of independent measurements was expressed in terms of the coefficient of variation (CV), where CV [%] 5 (standard deviation/mean) x 100. Nonparametric Wilcoxon signed rank test was used to analyze paired comparisons. Unpaired pairwise comparisons were performed among multiple groups using the Mann-Whitney test and overall multiple group comparisons were done using Kruskal-Wallis test using the freely available Past statistics software (http://nhm2.uio.no/norlex/past/download.html). Plots were generated and linear regression fit was performed using Prism (Graphpad software version 6). Staining index for the multimer channels were calculated as 5 F p 2 F n 2r n , where F p 5 median fluorescence of the CD8 1 multimer (1) population, F n 5 median fluorescence of the CD8 (1) multimer (-) population, and r n 5 standard deviation of the CD8 1 multimer (-) population (29) .
General Laboratory Operation
The laboratory operates under exploratory research conditions using qualified assays and established protocols; it is regularly participating in proficiency panels for the multimer staining assay. Experiments were performed by experienced flow cytometry users.
RESULTS Specificity
We assessed both the nonspecific binding (referred to as the background staining) and the specific binding of multimers. Nonspecific binding was addressed in several ways. In our experience as well as in several published studies (24, 30) , multimers generally display very low background stainings (0.02% of CD8 1 T cells). Therefore, a maximum threshold of 0.02% multimer (1) CD8 (1) cells was set as the background acceptance criteria.
First, PBMCs from 5 HLA-A*02 (-) donors were stained using 6 different HLA-A*02 multimers and their respective binding is shown in Figure 2A . PBMCs were always co-stained with 2 different multimer specificities, one conjugated to PE and the other to APC. CMV and Flu multimers (conjugated to PE and APC) were tested once and DDX5 multimers were tested twice on each donor. All multimers bound to less than 0.0130% CD8 (1) cells. PE multimers bound on average to 0.0036% and APC multimers bound to 0.0042% CD8 (1) cells. Wilcoxon signed rank test (paired) indicated that the nonspecific binding of the PE and APC multimers for the same specificities did not differ significantly (P 5 0.84). In addition, we observed no difference in the background binding of CMV multimers between CMV seropositive and CMV seronegative donors among the 5 HLA-A*02 (-) donors.
In a second experiment, binding of DDX5 (i.e., selfantigen) multimers to HLA-matched PBMCs was analyzed by staining PBMCs from 3 HLA-A*02 (1) donors with PEor APC-conjugated DDX5 multimers twice (Fig. 2B ). The mean percentage of DDX5 multimer (1) CD8 (1) cells was 0.0011% and 0.0004% for PE-and APC-multimers, respectively. Next, we tested the binding of CMV (1) PBMCs. Cells from 3 HLA-A*02 (1) donors (B1050, B1053, and B1054) were stained with either CMV-PE 1 DDX5-APC, CMV-APC 1 DDX5-PE, Flu M1-PE 1 DDX5-APC or Flu M1-APC 1 DDX5-PE multimer combinations. The results for DDX-5 multimer binding are shown. C: Binding of CMV multimers to CMV seronegative donors. Cells from 3 HLA-A*02 (1) CMV seronegative donors were stained with CMV-PE or CMV-APC multimers in 3 replicates. All scatter plots show the mean percentage of multimer (1) CD8 (1) cells (6 standard deviation (SD). D, E: Specificity of CMV and Flu multimers. PBMCs from 2 HLA-A*02 (1) donors B1071 (donor 1) and B1093 (donor 2) were incubated with 1 mg/ml of the indicated peptides for 4 h. Cells treated with the DDX5 peptide or with an equivalent volume of 10% DMSO served as negative controls. PBMCs were then stained with either CMV-PE 1 Flu-APC or CMV-APC 1 Flu-PE multimer mixes. The percentage of multimer (1) CD8 (1) cells and the staining index of the multimer (1) multimers (PE-and APC-labeled) to PBMCs from antigen-na€ ıve (CMV seronegative) HLA-A*02 (1) donors (n 5 3). Tests were performed in triplicates. On average, the CMV-PE multimer bound to 0.0016% (median 5 0.0015%) and the CMV-APC multimer bound to 0.0100% (median 5 0.0016%) of the CD8 (1) cells. (Fig. 2C) . Additionally, we compared the binding of CMV multimers between the 5 HLA-A*02 (-) donors and the 3 CMV seronegative HLA-A*02 (1) donors and found no significant difference (PE multimers, P 5 0.72; APC multimers, P 5 0.79). Finally, in stainings combining CMV and Flu multimers on HLA-A*02 (1) donors (n 5 3), we did not observe any double-multimer positive event, further indicating the excellent specificity of the multimers.
We finally performed an additional exploratory experiment to address a further aspect of the specificity of the CMV and Flu multimers. Here, we relied on the principle of TCR internalization after it has engaged an HLA molecule presenting its cognate peptide (31, 32) . We incubated PBMCs from 2 HLA-A*02 (1) donors with CMV and/or Flu synthetic peptides, or with the self-protein peptide DDX5 (same as those used for monomer synthesis) for 4 h to induce TCR internalization; the cells were then stained with PE-and APC-conjugated CMV and Flu multimers. Since the downregulation of the TCR expression at the cell surface is generally not complete, multimer (1) cells were still detectable; however, both the % and the mean fluorescence of multimer (1) CD8 (1) cells were reduced in all cases. Hence, analysis was done using 2 alternative gates. One gate was set on the staining performed in the absence of specific peptide preincubation (i.e. on the DMSO control) and was used to quantify a reduction in the % of multimer positive cells (Supporting Information Fig. 2B ). Another gate that included all multimer positive cells even in the presence of the specific peptide was used to calculate the staining index of the multimer positive population (Supporting Information Fig. 2C ). In both cases, specificity of the multimers was confirmed by the reduction of multimer staining (> 70%), after incubation with the relevant peptides, for both the % and the staining index of the multimer (1) cell population as compared to the DMSO control. No TCR downregulation was observed in the control conditions DDX5 or irrelevant viral-derived peptide ( Figs. 2D and 2E ).
Precision
We assessed the precision by calculating the CV of multiple multimer stainings and of their analysis (33) . Intra-and inter-assay variabilities were determined by staining PBMCs from 3 HLA-A*02 (1) donors with PE-or APC-conjugated CMV and Flu multimers in 3 replicates on 3 different days. Triplicates on the same day were stained using the same multimer master mix. Based on the 9 stainings, T-cell reactivities were then stratified into high, intermediate and low frequencies (Supporting Information Fig. 1) .
We calculated the CV of triplicates from each of the 3 days and the average is reported as the intra-assay CV (Fig. 3A) . The overall intra-assay CV for all stainings was 3.9% and thus passed the acceptance criteria (CV < 10%). In addition, although not specified in the validation plan, we analyzed the CVs for each frequency category separately: detection of low frequency cells (Flu specific cells in donor B1050) showed maximum variability (mean CV5 10.3%) in the technical replicates, followed by intermediate frequency (Flu specific cells in donors B1053 and B1054) (mean CV 5 4%) and high frequency (CMV specific cells in donors B1050, B1053, and B1054) (mean CV 5 1.7%).
We then assessed the mean % of multimer (1) CD8 (1) cells of triplicate stainings from each day, and the CV of these 3 mean values is reported as the inter-assay CV (Fig. 3B ). Overall CV was 2.9% (3.7% for low, 3.8% for intermediate and 2.1% for high frequency antigenspecific T cells) and passed the acceptance criteria (CV < 20%). Wilcoxon matched pairs signed rank test indicated no significant difference between the PE and APC stainings performed for the same antigen specificities in the 3 days (CMV multimer P 5 0.09, Flu multimer P 5 0.33).
Next, we analyzed the variability when 3 operators independently performed and analyzed the stainings in triplicates. For this, the data from 1 out of 3 experiments in Figure 3A and an additional experiment performed by 2 other individuals were used. Thereafter the inter-individual variability of experiment was calculated using 2 approaches (acceptance criteria5 CV < 25%). In the first approach, the variability within the triplicate stainings by each individual was calculated (Fig. 3C) ; the overall CV was 4.7%. CV was highest while quantifying low frequency cells (mean CV5 12.11%) followed by intermediate (mean CV5 5%) and high frequency (mean CV5 2.1%). In the second approach, we calculated the average of triplicate stainings by each individual and determined the CV to be 7.8% (CV for low5 5.5%, inter-mediate5 9.4% and high frequency5 7.6%, data not shown).
Manual analysis is a known source of variability in flow cytometry assays (34) (35) (36) (37) (38) . We therefore addressed the contribution of data analysis to the variability of the multimer assay. FCS files from one of the inter assay variability experiments (multimer stainings on PBMCs from 3 HLA-A*02 (1) donors in triplicates) were analyzed by 3 individuals independently but following a harmonized gating strategy. The CV was calculated for the analysis of each replicate separately (Fig. 3D ). We found that the overall inter-operator CV was 2.4% (acceptance criteria CV < 5%), 3.8% for low, 2.7% for intermediate and 1.7% for high frequency cells.
Altogether, we observed higher inter/intra assay as well as inter-individual variability while staining and analyzing low frequencies; still the assay satisfied the acceptance criteria for all aspects of precision.
Linearity
We tested the linearity of our method by generating 9 cell samples containing predictable numbers of antigen-VALIDATION OF THE HLA-MULTIMER STAINING ASSAY specific cells. Sample 1 contained only cells from B1054 (HLA-A*02 (1) , CMV and Flu specificities at high and intermediate frequencies, respectively). Sample 9 contained only cells from B1060 (HLA-A02 (-) ). B1054 cells were serially diluted (halved in subsequent dilutions) into B1060 PBMCs in samples 2 to 8. Cells were then stained with either CMV-PE 1 Flu-APC or with CMV-APC 1 Flu-PE multimers (one replicate per staining). Since the 2 donors had different frequencies of CD8 (1) T cells, percentages of multimer (1) cells were calculated among lymphocytes. Percentage of multimer (1) cells in sample 1 served to predict the frequency of multimer (1) cells in the diluted samples. Plotting these predicted frequency of multimer (1) cells against the measured FIG. 3 . Precision of the multimer assay. A: Intra assay variability. PBMCs from 3 HLA-A*02 (1) donors (B1050, B1053, and B1054) were stained with CMV-PE 1 Flu-APC or CMV-APC 1 Flu-PE in triplicates on 3 different days and the % multimer (1) CD8 (1) determined. CV [%] was calculated from each triplicate and the mean CV [%] is plotted. B: Inter assay variability. From the stainings in A, the mean percentage of multimer (1) frequencies revealed a high goodness of fit for a linear regression (R 2 > 0.99) ( Fig. 4) , hence passing the acceptance criteria (R 2 > 0.95).
The detection limit of the assay depends on the level of background staining. All 4 multimers bound less than 0.002% CD8 (1) cells in sample 9 (not shown), in line with our findings in the specificity experiment (Fig. 1A) . Sample 1 contained 2.45% CMV multimer (1) CD8 (1) cells and 0.36% Flu multimer (1) CD8 (1) cells. The lowest dilution (sample 8) contained 0.04% CMV multimer (1) CD8 (1) cells and 0.011% Flu multimer (1) CD8 (1) cells (all frequencies are the average of PE and APC stainings). Since the assay followed a linear regression throughout the tested range, we report 0.011% CD8 (1) cells as the lower limit of detection (LLOD) and the lower limit of quantitation (LLOQ) that we validated for this assay. Also, PE-and APC-multimer stainings did not differ significantly with respect to the % of multimer (1) cells detected (Wilcoxon matched-pairs signed rank test, P 5 0.89).
Sensitivity
Sensitivity was assessed using the data from the linearity experiment described above. Fold changes (ratios) in the percentage of multimer (1) lymphocytes from two successive samples were calculated; according to the serial dilutions that we performed, these percentages should theoretically differ by a factor 2. We assigned a tolerance of 20%, 1.6 fold to 2.4 fold, to be registered between successive samples for our assay to be sensitive in that range. Table 1 shows the ratios (averaged PE-and APC-multimer stainings) of multimer (1) lymphocytes between successive samples. According to our analysis, ratio of samples 1 through to 7 and samples 1 through to 6 fell within the tolerance limit for CMV and Flu multimers respectively. Hence, based on the mean of 2 FIG. 4. Linearity of the multimer assay. PBMCs from HLA-A*02 (1) donor B1054 were serially diluted into PBMCs from an HLA-A*02 (-) donor B1060 to generate 8 samples (containing 2x10 6 cells each). The predicted percentages of multimer (1) lymphocytes in each sample was plotted against the measured percentages obtained after staining of the cells with CMV-PE 1 Flu-APC or with CMV-APC 1 Flu-PE multimers. Samples 1-8 are shown on a log scale for better visualization and the R 2 of linear regression is indicated. stainings (1 x PE and 1 x APC), the assay was sensitive above 0.064% CMV multimer (1) CD8 (1) cells (Sample 7) and 0.026% Flu multimer (1) CD8 (1) cells (Sample 6).
Robustness
Immunomonitoring of patient PBMCs is often limited by the total number of cells available for the assay. We therefore tested the robustness of the multimer assay with respect to the number of cells stained or analyzed.
Six decreasing numbers of PBMCs from donor B1053 were stained using CMV-PE 1 Flu-APC or CMV-APC 1 Flu-PE multimer mixes and in duplicates, and the % of multimer positive CD8 (1) cells were assessed (Fig.  5A) . All the different cell numbers stained gave comparable final percentages of the high frequency CMV multimer (1) CD8 (1) cells (Mann-Whitney pairwise comparisons of the mean of 4 stainings (PE and APC), P > 0.05). The average CVs of stains performed were in line with the earlier determined intra-assay CV for detecting high frequencies (Fig. 3) . While quantifying intermediate frequency Flu-specific cells, we also did not observe a significant difference between the percentages of Flu- Percentage of multimer (1) lymphocytes in samples 1 to 8 from the experiment shown in Figure 4 were taken to address sensitivity of the assay. The ratios of multimer (1) lymphocytes in successive samples were calculated for CMV and Flu specificities for both PE and APC multimers. The first column of the table indicates the samples that were compared. The mean of the ratios of PE and APC stainings is indicated for CMV and Flu alongside. Grey cells indicate that between those 2 samples, the assay did not fulfill the validation criteria of ratio 1.6 2 2.4.
FIG. 5. Robustness of the multimer assay. A,B: Impact of no. of cells stained: The indicated no. of cells from donor B1053 were stained with CMV-PE 1 Flu-APC or CMV-APC 1 Flu-PE multimer mixes in duplicates. All cells were acquired for each stain and the average no. of cells acquired for the total number of cells stained were, 187992 for 0.25x10 6 , 382846 for 0.5x10 6 , 675750 for 1x10 6 , 1018750 for 1.5x10 6 , 1385000 for 2x10 6 and 2005000 for 3x10 6 cells. C and D. impact of the no. of cells acquired: 1.5x10 6 cells were stained in 6 replicates using CMV-PE 1 Flu M1-APC or CMV-APC 1 Flu-PE multimer mixes, pooled and the indicated cell number were acquired on the cytometer in duplicates. Scatter plots show the percentages of multimer (1) CD8 (1) for CMV (left) and Flu (right) specificities. Mean of all stainings (6 SD) are indicated. specific CD8 (1) cells for any of the different cell numbers stained. Intra assay variability was in the range of acceptance, except for the 4 stainings using 0.25 x 10 6 cells (CV 5 19.6%) ( Fig. 5B) .
Next, 1.5 x 10 6 cells from the same donor were stained in 6 replicates with CMV-PE 1 Flu-APC or CMV-APC 1 Flu-PE multimer mixes. After staining, all 6 replicates were pooled and 1.5 x 10 6 , 1 x 10 6 , 0.5 x 10 6 or 0.25 x 10 6 cells were acquired in duplicates on the flow cytometer by stopping cell acquisition once the above mentioned events were acquired. The percentage of multimer (1) CD8 (1) cells obtained in each case was not significantly different for CMV-specific cells or Fluspecific cells (Mann-Whitney pairwise comparisons, p > 0.05) ( Figs. 5C and 5D ). Furthermore, the CV of replicates (altogether n 5 4 tests with PE and APC multimers) showed acceptable inter-stain variability for high frequency CMV-specific cells (1.8% to 4.2%). However, the CV of detection of intermediate frequency Fluspecific cells was increased when <1 x 10 6 cells were analyzed (CV5 11.6% to 15.8%) compared to the analysis of 1 x 10 6 or more cells (CV5 2.2% to 8.9%). Altogether, variability appeared to increase when < 70 Fluspecific cells were measured. These experiments underline the importance of acquiring sufficient number of cells when the cells to be detected are rare (11) .
DISCUSSION
Even though validation of T cell immunomonitoring assays has become a pre-requisite in clinical trials, there is currently no standard guideline on how and which parameters should be addressed. One reason might be that such assays are highly complex due to the heterogeneity of the analyte (i.e., the cell product). Additionally, within the same assay, reagents and conditions might change from one laboratory to another or within the same laboratory over time. Hence, it is important that individual centers first insure that their assay compares to that of other expert laboratories and then validate this assay using their in-house protocols and own reagents before applying them for assessing clinical efficacy of immunotherapeuticals. Note here that once an assay has been successfully validated, regular control of performance should be performed to maintain assay quality overtime. Reference cell samples and periodic participation to proficiency panels are efficient tools to insure the development and maintenance of high performing assays (12, 15, 39) .
The multimer assay is broadly applied for assessing the impact of T-cell based immunotherapies on the T cell repertoire, e.g. to test the effect of immune checkpoint therapy on the induction or broadening of antitumor specific T cell responses (40, 41) . Our primary application of the multimer assay is to quantify natural or vaccine-induced antigen-specific CD8 1 T cells in cancer patients (42, 43) . Our and othe rs vaccination approach relies on the immunization of patients with a cocktail of peptides covering several HLA-alleles and tumor associated antigens that may be tailored to each patient individually (44) (45) (46) . In this context, we decided to validate the assay itself rather than the individual multimers, and used CMV and Flu as model antigens, coupled to the most commonly used fluorochromes PE and APC. Instead of using T cell clones for different specificities, we used cryopreserved PBMCs from healthy donors as these are physiologically close to clinical samples containing T cell memory subsets and can be obtained in sufficient amounts.
The multimer assay in our laboratory has been well established and standardized over the years, following the CIP guidelines as well as through regular participation in harmonization panels and inter-laboratory optimization. Through this process, the assay qualified for validation and the experience gained enabled us to design the experiments for the validation and, very importantly, to set the acceptance criteria for each parameter (Supporting Information Figure 3 and Supporting Information Table 1 ). Note that the assay should be re-evaluated if one parameter fails to meet the set acceptance criteria. First, probable reasons for the failure must be investigated and when identified (e.g. problem with reagents, protocols or mistakes by operators), the assay should be repeated. If no obvious reason can be found, the acceptance criteria might need to be revised, and the assay must be repeated, keeping in mind that the revised acceptance criteria should still be serving the purpose of assay.
The multimer staining assay is immensely valuable for the detection of rare cell populations. Specificity of the assay will be compromised upon increased nonspecific multimer binding or background staining. Assay specificity, validated by testing the unspecific multimer binding, met our acceptance criteria and was similar to that reported in another validation study (Fig. 2 , < 0.013%) (24) . Although the same background values might not be valid for all specificities, for in vitro stimulated cells or in the setting of a combinatorial staining, the low background levels in these model antigen multimers indicate that the assay itself is highly specific. When necessary, specific binding of individual multimers may be qualified in several ways. The presence of the correct peptide within the HLA binding groove can be easily confirmed by mass spectrometry (data not shown), or by using a more functional approach quantifying the peptide-induced internalization of the cognate TCRs (Fig. 2) .
The reproducibility of successive multimer stainings in the intra assay, inter assay and inter individual settings passed the pre-set acceptance criteria ( Fig. 3) yielding CVs at par with similar studies (<10%) (24, 25) . Interestingly we observed a general trend of increased variability when low frequency cells were quantified, which is well in-line with results of proficiency panels that have shown an increased inter-laboratory variation in the reported frequencies of low frequency T cells (<0.1% of the CD8 (1) subset) (11, 35) .
In a multimer staining assay, if all antigen-specific cells bind the relevant multimers, the number of antigen-specific cells present in the cell suspension and the number of cells binding the multimers should correlate. While the maximum possible upper limit of quantification is 100% multimer (1) , the background nonspecific binding of the multimer contributes to the lower limit of detection of the assay. Taking cues from previously reported analysis of this parameter (24, 25) , we expected a high degree of linear correlation between the number of antigen-specific cells in the sample and the actual frequencies reported by the assay. Indeed, we observed a very good linear correlation between the actual and measured frequencies (R 2 > 0.99), up to about 0.01% of multimer (1) CD8 (1) cells, making the assay extremely potent at detecting rare cell populations (Fig. 4) .
In order to improve our understanding of the assay, we also included some exploratory parameters, like sensitivity and robustness.
Sensitivity of an assay is often misinterpreted by reporting the limit of detection. However, sensitivity reflects the ability to report changes in the amount of analyte in the sample, whereby detection of smaller changes reflects greater sensitivity (47) . Within the set tolerance levels (2 fold 620%), the multimer staining assay was sensitive down to 0.026% of multimer (1) CD8 (1) cells (Table 1) , a frequency close to the background limit and the lower limit of detection.
We addressed assay robustness with varying amount of available sample material, a ubiquitous limiting factor when monitoring clinical samples, with respect to the changes in number of cells stained or number of cells acquired. All the tested cell numbers gave comparable results. However, it is worth mentioning that the detection of intermediate frequencies, compared to high frequencies, displayed higher variability (CV) within multiple stainings (Fig. 5 ). This stresses the necessity to measure a sufficient number of cells (at least 70,000 to 100,000 CD8 (1) cells as seen in our validation) to reproducibly detect rare cell populations. This is of high relevance for measuring tumor antigen-specific T cells which are in most cases present at very low frequencies in the blood of cancer patients, even after vaccination (11) .
In summary, we performed specific experiments for each of the validation criteria to be addressed, and could successfully validated the HLA-peptide multimer staining assay. We furthermore provide a validation strategy with detailed outlines on the various parameters and the underlying steps to be followed during the validation of a multimer assay. A similar approach may be taken for validating other cellular immunoassays for which the same basic parameters need to be addressed and the reported validation strategies can be transferred.
